CARF and lymphoma: The marked suppression of cell proliferation by the non‐phosphorylation variant of CARF indicates the potential of modulating CARF phosphorylation as a strategy for lymphoma therapy and suggests that these phosphorylation sites could be viable targets for lymphoma‐specific drugs, shedding light on the phosphorylation‐based application in lymphoma therapy at the amino acid level.